Thera-SAbDab

MOTAVIZUMAB

>   Structural Summary
TherapeuticMotavizumab
TargetRespiratory Syncytial Virus Glycoprotein F
Heavy ChainQVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS
Light ChainDIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK
100% seqID Fv Structure3ixt [Fvs: AB, HL], 3qwo [Fvs: AB, HL], 4zyp [Fvs: JL, KM, NO], 6oe5 [Fvs: BC], 6ywd [Fvs: AB]
99% seqID Fv Structure4jlr [Fvs: AB, HL], 5k8a [Fvs: BA, FE, HL, VM]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Motavizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 31A 31B 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 101 102 103 104 105 106 107 108 109 110 111 112 113
motavizumab Q V T L R E S G P A L V K P T Q T L T L T C T F S G F S L S T A G M S V G W I R Q P P G K A L E W L A D I W W D D K K H Y N P S L K D R L T I S K D T S K N Q V V L K V T N M D P A D T A T Y Y C A R D M I F N F Y F D V W G Q G T T V T V S S
5k8a E V T L R E S G P A L V K P T Q T L T L T C T F S G F S L S T A G M S V G W I R Q P P G K A L E W L A D I W W D D K K H Y N P S L K D R L T I S K D T S K N Q V V L K V T N M D P A D T A T Y Y C A R D M I F N F Y F D V W G Q G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
motavizumab D I Q M T Q S P S T L S A S V G D R V T I T C S A S S R V G Y M H W Y Q Q K P G K A P K L L I Y D T S K L A S G V P S R F S G S G S G T E F T L T I S S L Q P D D F A T Y Y C F Q G S G Y P F T F G G G T K V E I K
5k8a D I Q M T Q S P S T L S A S V G D R V T I T C S A S S R V G Y M H W Y Q Q K P G K A P K L L I Y D T S K L A S G V P S R F S G S G S G T E F T L T I S S L Q P D D F A T Y Y C F Q G S G Y P F T F G G G T K V E I K
Sequence identity: 96.89%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 31A 31B 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 101 102 103 104 105 106 107 108 109 110 111 112 113
motavizumab Q V T L R E S G P A L V K P T Q T L T L T C T F S G F S L S T A G M S V G W I R Q P P G K A L E W L A D I W - W D D K K H Y N P S L K D R L T I S K D T S K N Q V V L K V T N M D P A D T A T Y Y C A R D M I F N F Y F D V W G Q G T T V T V S S
4jlr Q V T L R E S G P A L V K P T Q T L T L T C T F S G F S L S T A G M S V G W I R Q P P G K A L E W L A D I W W D - D K K H Y N P S L K D R L T I S K D T S A N Q V V L K V T N M D P A D T A T Y Y C A R D M I F N F Y F D V W G Q G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
motavizumab D I Q M T Q S P S T L S A S V G D R V T I T C S A S S R V G - Y M H W Y Q Q K P G K A P K L L I Y D T S K L A S G V P S R F S G S G S G T E F T L T I S S L Q P D D F A T Y Y C F Q G S G Y P F T F G G G T K V E I K
4jlr D I Q M T Q S P S T L S A S V G D R V T I T C S A S S R V - G Y M H W Y Q Q K P G K A P K L L I Y D T S K L A S G V P S R F S G S G S G T A F T L T I S S L Q P D D F A T Y Y C F Q G S G Y P F T F G G G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '24)Phase-III
Estimated Status (Aug '24)Discontinued
Recorded Developmental TechnologyAffinity Matured from Palivizumab
INN Year Proposed2006
INN Year Recommended2007
Companies InvolvedMedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRespiratory syncytial virus infections
NotesBiosimilars available

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy